Phi Pharma SA is a private Swiss-based biopharmaceutical company. It specializes in the discovery to early clinical development of drug conjugates for improving treatment of diseases with high-medical need. Phi Pharma technology allows development of a powerful new class of peptide drug conjugates through specific cellular targeting and efficient intra-cellular delivery. Company programs are in oncology and infectious diseases.